About
Specialty Pharmaceuticals
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (15)
Brian T. Walsh, MBA,Chief Commercial Officer
,Chief Commercial Officer
HLS Therapeutics
team_member
Christian Roy,Director, Independent
,Director, Independent
HLS Therapeutics
board_member
Christine Elliott,Director, Independent
,Director, Independent
HLS Therapeutics
board_member
Craig Millian
,Director, Chief Executive Officer
HLS Therapeutics
executive
Craig Millian, MBA,Chief Executive Officer
,Chief Executive Officer
HLS Therapeutics
executive
Experienced across all stages of the product lifecycle
HLS Therapeutics
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
0
As Collaborator
3
Total Enrollment
370
By Phase
PHASE4: 1PHASE2: 1
By Status
COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT05271591Collaborator
Generalizability of REDUCE-IT Results to People of South Asian Descent With Atherosclerotic Cardiovascular Disease in Canada (REDUCE-IT Canada SA)
N/ACompleted
200 participants
Started: Mar 5, 2022 · Completed: Apr 9, 2022
NCT04562467Collaborator
The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
PHASE4Completed
70 participants
Started: Sep 24, 2020 · Completed: May 25, 2023
NCT04412018Collaborator
An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
PHASE2Completed
100 participants
Started: Jun 4, 2020 · Completed: Dec 12, 2020
Locations (1)
Headquarters
Etobicoke, ON, Canada
Map
Loading map...